NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $8,487,000 | -25.0% | 494,568 | -12.6% | 0.30% | -18.2% |
| Q1 2021 | $11,322,000 | +17.2% | 566,082 | -0.4% | 0.37% | +8.5% |
| Q4 2020 | $9,662,000 | -1.8% | 568,379 | -4.1% | 0.34% | -14.1% |
| Q3 2020 | $9,837,000 | -24.9% | 592,930 | +4.8% | 0.40% | -29.7% |
| Q2 2020 | $13,105,000 | +25.8% | 565,833 | -3.0% | 0.56% | -3.3% |
| Q1 2020 | $10,416,000 | -19.2% | 583,525 | -2.2% | 0.58% | +33.5% |
| Q4 2019 | $12,885,000 | +14.5% | 596,928 | -3.4% | 0.44% | +8.5% |
| Q3 2019 | $11,251,000 | -49.8% | 617,674 | -2.0% | 0.40% | -46.0% |
| Q2 2019 | $22,415,000 | -0.5% | 629,999 | -6.0% | 0.74% | +2.8% |
| Q1 2019 | $22,524,000 | +5.6% | 670,359 | +3.3% | 0.72% | -6.8% |
| Q4 2018 | $21,333,000 | -22.9% | 649,002 | +42.9% | 0.78% | -21.5% |
| Q3 2018 | $27,678,000 | +21.9% | 454,032 | -2.3% | 0.99% | +20.1% |
| Q2 2018 | $22,700,000 | -53.7% | 464,883 | +0.8% | 0.82% | -56.9% |
| Q1 2018 | $48,985,000 | -20.3% | 460,993 | -55.2% | 1.91% | -20.9% |
| Q4 2017 | $61,472,000 | +107.0% | 1,029,332 | -16.8% | 2.42% | +83.9% |
| Q3 2017 | $29,695,000 | +17.8% | 1,237,309 | -4.1% | 1.31% | +19.9% |
| Q2 2017 | $25,214,000 | +4.8% | 1,289,717 | +25.8% | 1.10% | -6.5% |
| Q1 2017 | $24,060,000 | +90.6% | 1,025,147 | -0.4% | 1.17% | +84.0% |
| Q4 2016 | $12,624,000 | -29.9% | 1,028,819 | -1.8% | 0.64% | -32.3% |
| Q3 2016 | $18,000,000 | +35.6% | 1,047,750 | +12.3% | 0.94% | +23.0% |
| Q2 2016 | $13,276,000 | +4.9% | 932,933 | +1.4% | 0.76% | +4.8% |
| Q1 2016 | $12,652,000 | -16.5% | 920,121 | +2.3% | 0.73% | -15.7% |
| Q4 2015 | $15,157,000 | +164.9% | 899,531 | +72.3% | 0.87% | +134.1% |
| Q3 2015 | $5,721,000 | -4.8% | 521,967 | +8.7% | 0.37% | +6.6% |
| Q2 2015 | $6,007,000 | +3.5% | 480,161 | -9.0% | 0.35% | +3.3% |
| Q1 2015 | $5,803,000 | -18.6% | 527,575 | +14.7% | 0.34% | -22.4% |
| Q4 2014 | $7,131,000 | +53.4% | 460,093 | +19.4% | 0.43% | +33.6% |
| Q3 2014 | $4,650,000 | +100.0% | 385,244 | +112.4% | 0.32% | +107.7% |
| Q2 2014 | $2,325,000 | +54.7% | 181,338 | +46.3% | 0.16% | +41.8% |
| Q1 2014 | $1,503,000 | +92.4% | 123,990 | +80.3% | 0.11% | +96.4% |
| Q4 2013 | $781,000 | +192.5% | 68,787 | +169.4% | 0.06% | +115.4% |
| Q3 2013 | $267,000 | -25.2% | 25,538 | -17.4% | 0.03% | -25.7% |
| Q2 2013 | $357,000 | – | 30,927 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |